Group 1: Earnings Performance - Amcor reported quarterly earnings of $0.20 per share, missing the Zacks Consensus Estimate of $0.21 per share, and down from $0.21 per share a year ago, representing an earnings surprise of -4.76% [1] - The company posted revenues of $5.08 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1.76%, and up from $3.54 billion year-over-year [2] - Over the last four quarters, Amcor has not surpassed consensus EPS or revenue estimates [2] Group 2: Stock Performance and Outlook - Amcor shares have increased by approximately 5.6% since the beginning of the year, compared to a 10% gain in the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is $0.20 on revenues of $5.86 billion, and for the current fiscal year, it is $0.82 on revenues of $23.6 billion [7] Group 3: Industry Context - The Containers - Paper and Packaging industry, to which Amcor belongs, is currently ranked in the bottom 19% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Amcor's stock performance [5][6]

VAXART, INC. (VXRT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.09 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of +22.22%. A quarter ago, it was expected that this company would post a loss of $0.07 per share when it actually produced a loss of $0.07, delivering no surprise. Over the last four quarters, the company has surpassed cons ...

分组1 - IceCure Medical Ltd. reported quarterly earnings of $0.06 per share, surpassing the Zacks Consensus Estimate of a loss of $0.06 per share, representing an earnings surprise of +200.00% [1] - The company posted revenues of $0.53 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 34.38%, and a decline from $1.01 million in the same quarter last year [2] - IceCure Medical shares have decreased by approximately 25.5% since the beginning of the year, contrasting with the S&P 500's gain of 9.6% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.06 on $1 million in revenues, and for the current fiscal year, it is -$0.20 on $6.85 million in revenues [7] - The Zacks Industry Rank indicates that the Medical Services sector is currently in the bottom 39% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8]

分组1 - Ovid Therapeutics reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.16, representing an earnings surprise of +62.50% [1] - The company posted revenues of $6.27 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4,225.52%, compared to revenues of $0.17 million a year ago [2] - Ovid Therapeutics has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates three times [2] 分组2 - The stock has underperformed, losing about 41.4% since the beginning of the year, while the S&P 500 gained 9.6% [3] - The current consensus EPS estimate for the coming quarter is -$0.14 on $0.1 million in revenues, and for the current fiscal year, it is -$0.60 on $0.52 million in revenues [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Company Performance - Sanara MedTech Inc. reported a quarterly loss of $0.23 per share, better than the Zacks Consensus Estimate of a loss of $0.33, and an improvement from a loss of $0.41 per share a year ago, representing an earnings surprise of +30.30% [1] - The company posted revenues of $25.83 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.70%, and showing an increase from $20.16 million in the same quarter last year [2] - Over the last four quarters, Sanara MedTech has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Sanara MedTech shares have declined approximately 17.3% since the beginning of the year, contrasting with the S&P 500's gain of 9.6% [3] - The current Zacks Rank for Sanara MedTech is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.32 on revenues of $26.65 million, and for the current fiscal year, it is -$1.56 on revenues of $106.93 million [7] - The trend of estimate revisions for Sanara MedTech was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical - Products industry, to which Sanara MedTech belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Company Performance - Durect (DRRX) reported a quarterly loss of $0.07 per share, better than the Zacks Consensus Estimate of a loss of $0.13, representing an earnings surprise of +46.15% [1] - The company posted revenues of $0.45 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 39.69%, although this is a decline from year-ago revenues of $2.17 million [2] - Over the last four quarters, Durect has surpassed consensus EPS estimates two times and topped consensus revenue estimates once [2] Stock Performance - Durect shares have increased approximately 149.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.4% [3] - The current Zacks Rank for Durect is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.18 on $0.3 million in revenues, and for the current fiscal year, it is -$0.66 on $1.19 million in revenues [7] - The outlook for the Medical - Drugs industry, where Durect operates, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Group 1 - Armata Pharmaceuticals reported a quarterly loss of $0.32 per share, better than the Zacks Consensus Estimate of a loss of $0.39, and improved from a loss of $0.65 per share a year ago, resulting in an earnings surprise of +17.95% [1] - The company achieved revenues of $2.17 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 57.17%, compared to zero revenues a year ago [2] - Armata Pharmaceuticals shares have increased approximately 27.6% since the beginning of the year, outperforming the S&P 500's gain of 8.4% [3] Group 2 - The earnings outlook for Armata Pharmaceuticals is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Armata Pharmaceuticals was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.50 on $1.38 million in revenues, and -$1.94 on $5.5 million in revenues for the current fiscal year [7] Group 3 - The outlook for the Medical - Biomedical and Genetics industry, to which Armata Pharmaceuticals belongs, is currently in the bottom 43% of over 250 Zacks industries, which may impact stock performance [8] - Another company in the same industry, Invivyd, Inc., is expected to report a quarterly loss of $0.04 per share, reflecting a year-over-year change of +90%, with revenues projected at $15.5 million, up 585.8% from the previous year [9]

Company Performance - Alico reported a quarterly loss of $2.39 per share, significantly worse than the Zacks Consensus Estimate of a loss of $1.09, and compared to a loss of $0.27 per share a year ago, indicating a surprise of -119.27% [1] - The company posted revenues of $8.39 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 5.73%, and down from $13.61 million in the same quarter last year [2] - Over the last four quarters, Alico has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Outlook - Alico shares have increased by approximately 25% since the beginning of the year, outperforming the S&P 500's gain of 8.4% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates for the upcoming quarter at -$0.38 on $0.3 million in revenues, and -$10.41 on $44 million in revenues for the current fiscal year [4][7] - The estimate revisions trend for Alico was unfavorable prior to the earnings release, resulting in a Zacks Rank 5 (Strong Sell), indicating expected underperformance in the near future [6] Industry Context - The Agriculture - Operations industry, to which Alico belongs, is currently ranked in the bottom 21% of over 250 Zacks industries, suggesting a challenging environment for stock performance [8] - Another company in the same industry, Limoneira, is expected to report quarterly earnings of $0.19 per share, reflecting a year-over-year decline of 54.8%, with revenues projected at $54.7 million, down 13.6% from the previous year [9]

Company Performance - NeuroPace, Inc. reported a quarterly loss of $0.26 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.24, marking an earnings surprise of -8.33% [1] - The company posted revenues of $23.52 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 0.75% and showing an increase from $19.26 million in the same quarter last year [2] - Over the last four quarters, NeuroPace has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - NeuroPace shares have declined approximately 20.6% since the beginning of the year, contrasting with the S&P 500's gain of 8.4% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $24.32 million, and for the current fiscal year, it is -$0.85 on revenues of $95.36 million [7] Industry Outlook - The Medical - Instruments industry, to which NeuroPace belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact NeuroPace's stock performance [5]

Group 1 - Verrica Pharmaceuticals Inc. reported quarterly earnings of $0.02 per share, exceeding the Zacks Consensus Estimate of a loss of $0.7 per share, and showing a significant improvement from a loss of $3.1 per share a year ago, resulting in an earnings surprise of +102.86% [1] - The company achieved revenues of $12.7 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 154.04%, compared to revenues of $5.18 million in the same quarter last year [2] - Over the last four quarters, Verrica Pharmaceuticals has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Group 2 - The stock has underperformed the market, losing about 4.3% since the beginning of the year, while the S&P 500 has gained 8.4% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the upcoming quarter is -$0.60 on $7 million in revenues, and for the current fiscal year, it is -$3.00 on $21.7 million in revenues [7] Group 3 - The Medical - Drugs industry, to which Verrica Pharmaceuticals belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, IGC Pharma, Inc., is expected to report a quarterly loss of $0.03 per share, with revenues projected to be $0.33 million, reflecting a 22.2% increase from the year-ago quarter [9]